H.R. 1843 · 119th Congress (2025–2027)
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.
Referred to committee
Latest actionReferred to committee
This bill’s path
This is H.R. 1843’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
- Sponsor
- Rep. Neal P. Dunn (R-FL-2)
- Cosponsors
1 cosponsor
1 original · 0 later
- Rep. Kevin Mullin (D-CA-15)· Original · Mar 5, 2025
- Policy area
- Health
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Committees
Sep 17, 2025 · Markup
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (1)
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Official title, Display title · Introduced in House